BioCentury
ARTICLE | Company News

Supernus sales and marketing update

February 11, 2013 8:00 AM UTC

Supernus launched Oxtellar XR oxcarbazepine in the U.S. as an adjunctive therapy in the treatment of partial seizures in adults and children ages 6-17 years old. The wholesale acquisition cost for a ...